Schizophrenia Research
Volume 78, Issue 2 , Pages 147-156 , 15 October 2005

The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial

  • W. Wolfgang Fleischhacker

      Affiliations

    • Department of Biological Psychiatry, Medical University Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria
    • Corresponding Author InformationCorresponding author. Tel.: +43 512 504 23669; fax: +43 512 504 25267.
    • ,
  • Ireneus P.M. Keet

      Affiliations

    • Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, The Netherlands
    • ,
  • René S. Kahn

      Affiliations

    • Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, The Netherlands
    • ,
  • EUFEST Steering Committee

      Affiliations

    • The EUFEST Steering Committee: Austria: W. Wolfgang Fleischhacker, Principal Investigator (PI), Martina Hummer, Country Coordinator (CC) Department of Biological Psychiatry, Medical University Innsbruck, Innsbruck. Belgium: Jozef Peuskens (CC), Universitair Centrum St.-Jozef, Kortenberg. Bulgaria: Luchezar G. Hranov (CC ), University Hospital of Neurology and Psychiatry “St. Naum”, Sofia. Czech Republic: Jan Libiger (CC), Psychiatric Clinic and Department of Psychiatry, Charles University, Hradec Kralové. France: Sonja Dollfus (CC), Centre Esquirol-CHU de Caen, Caen Cedex. Germany: Wolfgang Gaebel (CC), Rheinische Kliniken Düsseldorf, Düsseldorf. Israel: Michael Davidson (CC), Sheba Medical Center, Tel Hashomer. Italy: Silvana Galderisi (CC), Department of Psychiatry, University of Naples SUN, Naples. Netherlands: René S. Kahn, Principal Investigator (PI) and Country coordinator (CC), University Medical Center Utrecht, Utrecht. I.P.M. Keet (Trial Co-ordinator until July 2004), Han Boter (current Trial Co-ordinator), University Medical Center Utrecht, Utrecht. Poland: Janusz Rybakowski (CC), Karol Marcinkowski University of Medical Sciences, Poznan. Romania: Mihai Gheorghe (CC), Central Military Hospital, Psychiatric Department, Bucharest. Spain: Juan-Jose Lopez Ibor (CC), Hospital Universitario San Carlos, Madrid. Sweden: Goran Sedvall (CC), Inst. Of Clinical Neuroscience, Psychiatry Section, Stockholm. Switzerland: Anita Riecher-Rössler (CC), Psychiatrische Universitätspoliklinik, Basel.

Received 12 May 2005 ,Revised 2 June 2005 ,Accepted 3 June 2005.

References 

  1. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr. Res. 1990;3:247–251
  2. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr. Bull. 1993;19:609–618
  3. Bagnall A, Lewis RA, Leitner ML. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database Syst. Rev. 2000;(4):(CD001945)
  4. Barnett D. Guidance on New (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. London: National Institute for Clinical Excellence (NICE); 2002;
  5. Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, Bates JA, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am. J. Psychiatry. 2000;157:549–559
  6. Brennan PA, Mednick SA, Hodgins S. Major mental disorders and criminal violence in a Danish birth cohort. Arch. Gen. Psychiatry. 2000;57:494–500
  7. Buse JB. Metabolic side effects of antipsychotics: focus on hyperglycemia and diabetes. J. Clin. Psychiatry. 2002;63(Suppl. 4):37–41
  8. Chatterjee A, Chakos M, Koreen A, Geisler S, Sheitman B, Woerner M, et al. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am. J. Psychiatry. 1995;152:1724–1729
  9. Cox D, Oakes D. Analysis of Survival Data. London: Chapman & Hall; 1984;
  10. Crow TJ, MacMillan JF, Johnson AL, Johnstone EC. A randomised controlled trial of prophylactic neuroleptic treatment. Br. J. Psychiatry. 1986;148:120–127
  11. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry. 2003;60:553–564
  12. Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Database Syst. Rev. 2003;(1):(CD001359)
  13. Emsley RA Risperidone Working Group. Risperidone in the treatment of first episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr. Bull. 1999;25:721–729
  14. Everitt BS. Analysis of longitudinal data. Beyond MANOVA. Br. J. Psychiatry. 1998;172:7–10
  15. Fleischhacker WW. The first-episode of schizophrenia: a challenge for treatment. Eur. Psychiatr. 2002;17(Suppl. 4):371–375
  16. Fleischhacker WW. Second-generation antipsychotics: discrepancies between licensed indications, evidence base and actual use. Psychopharmacology (Berl.). 2003;169:207–210
  17. Fleischhacker WW, Burns T. Feasibility of placebo-controlled clinical trials of antipsychotic compounds in Europe. Psychopharmacology (Berl.). 2002;162:82–84
  18. Flyckt L, Sydow O, Bjerkenstedt L, Edman G, Rydin E, Wiesel FA. Neurological signs and psychomotor performance in patients with schizophrenia, their relatives and healthy controls. Psychiatry Res. 1999;86:113–129
  19. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000;321:1371–1376
  20. Gerlach J, Korsgaard S, Clemmesen P, Lauersen AM, Magelund G, Noring U, et al. The St. Hans rating scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatr. Scand. 1993;87:244–252
  21. Hofer A, Hummer M, Kemmler G, Kurz M, Kurzthaler I, Fleischhacker WW. The safety of clozapine in the treatment of first-and multiple-episode patients with treatment-resistant schizophrenia. Int. J. Neuropsychopharmacol. 2003;6:201–206
  22. Hogarty GE, Schooler NR, Baker RW. Efficacy versus effectiveness. Psychiatr. Serv. 1997;48:1107
  23. Hotopf M, Churchill R, Lewis G. Pragmatic randomised controlled trials in psychiatry. Br. J. Psychiatry. 1999;175:217–223
  24. Huq ZU. A trial of low doses of risperidone in the treatment of patients with first-episode schizophrenia, schizophreniform disorder, or schizoaffective disorder. J. Clin. Psychopharmacol. 2004;24:220–224
  25. Johnson DA. Depressions in schizophrenia: some observations on prevalence, etiology, and treatment. Acta Psychiatr. Scand., Suppl. 1981;291:137–144
  26. Joy CB, Adams CE, Lawrie SM. Haloperidol versus placebo for schizophrenia. Cochrane Database Syst. Rev. 2001;(CD003082)
  27. Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos-Lorenzi J. Fluphenazine vs. placebo in patients with remitted, acute first-episode schizophrenia. Arch. Gen. Psychiatry. 1982;39:70–73
  28. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am. J. Psychiatry. 2003;160:13–23
  29. Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol. Psychiatry. 2001;50:873–883
  30. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry. 2000;157:514–520
  31. Kavanagh DJ, McGrath J, Saunders JB, Dore G, Clark D. Substance misuse in patients with schizophrenia: epidemiology and management. Drugs. 2002;62:743–755
  32. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13:261–276
  33. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res. 1988;23:99–110
  34. Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br. J. Psychiatr., Suppl. 1989;59–67
  35. Kemp R, Kirov G, Everitt B, Hayward P, David A. Randomised controlled trial of compliance therapy. 18-month follow-up. Br. J. Psychiatry. 1998;172:413–419
  36. Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT. A separate disease within the syndrome of schizophrenia. Arch. Gen. Psychiatry. 2001;58:165–171
  37. Langendam MW, van Brussel GH, Coutinho RA, van Ameijden EJ. The impact of harm-reduction-based methadone treatment on mortality among heroin users. Am. J. Public Health. 2001;91:774–780
  38. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr. Res. 1999;35:51–68
  39. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 2003;361:1581–1589
  40. Lezak MD. Neuropsychological Assessments. Oxford: Oxford University Press; 1995;
  41. Lieberman JA, Sheitman B, Chakos M, Robinson D, Schooler N, Keith S. The development of treatment resistance in patients with schizophrenia: a clinical and pathophysiologic perspective. J. Clin. Psychopharmacol. 1998;18:20S–24S
  42. Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs. chlorpromazine. Neuropsychopharmacology. 2003;28:995–1003
  43. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am. J. Psychiatry. 2003;160:1396–1404
  44. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand., Suppl. 1987;334:1–100
  45. Martin RL, Cloninger CR, Guze SB, Clayton PJ. Frequency and differential diagnosis of depressive syndromes in schizophrenia. J. Clin. Psychiatry. 1985;46:9–13
  46. May PR, Tuma AH, Dixon WJ, Yale C, Thiele DA, Kraude WH. Schizophrenia. A follow-up study of the results of five forms of treatment. Arch. Gen. Psychiatry. 1981;38:776–784
  47. Mota NE, Lima MS, Soares BG. Amisulpride for schizophrenia. Cochrane Database Syst. Rev. 2002;(2):(CD001357)
  48. Müller P. Zur Recidivprophylaxe Schizophrener Psychosen. Stuttgart: Enke; 1982;
  49. Oldfield RC. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia. 1971;9:97–113
  50. Phelan M, Slade M, Thornicroft G, Dunn G, Holloway F, Wykes T, et al. The Camberwell Assessment of Need: the validity and reliability of an instrument to assess the needs of people with severe mental illness. Br. J. Psychiatry. 1995;167:589–595
  51. Pocock SJ. Clinical Trials: A Practical Approach. Chichester: Wiley; 1993;
  52. Priebe S, Huxley P, Knight S, Evans S. Application and results of the Manchester Short Assessment of Quality of Life (MANSA). Int. J. Soc. Psychiatry. 1999;45:7–12
  53. Ringo DL, Half LM, Faustman WO. Validating the St. Hans rating scale with the abnormal involuntary movement scale (AIMS) in the assessment of tardive dyskinesia. J. Clin. Psychopharmacol. 1996;16:94–95
  54. Robinson DG, Woerner MG, Alvir JM, Geisler S, Koreen A, Sheitman B, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am. J. Psychiatry. 1999;156:544–549
  55. Roland M, Torgerson DJ. What are pragmatic trials?. BMJ. 1998;316:285
  56. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA. 2003;290:2693–2702
  57. Rummel C, Hamann J, Kissling W, Leucht S. New generation antipsychotics for first episode schizophrenia. Cochrane Database Syst. Rev. 2003;(4):(CD004410)
  58. Rybakowski JK, Borkowska A. Eye movement and neuropsychological studies in first-degree relatives of schizophrenic patients. Schizophr. Res. 2002;54:105–110
  59. Sands JR, Harrow M. Depression during the longitudinal course of schizophrenia. Schizophr. Bull. 1999;25:157–171
  60. Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C, Tollefson GD. Olanzapine versus haloperidol treatment in first-episode psychosis. Am. J. Psychiatry. 1999;156:79–87
  61. Sartorius N, Fleischhacker WW, Gjerris A, Kern U, Knapp M, Leonard BE, et al. The usefulness and use of second generation antipsychotic medication. Curr. Opin. Psychiatry. 2002;15(Suppl. 1):S1–S51
  62. Sartorius N, Fleischhacker WW, Gjerris A, Kern U, Knapp M, Leonard BE, et al. The usefulness and use of second generation antipsychotic medication. Curr. Opin. Psychiatry. 2003;16(Suppl. 1):S44
  63. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J. Chronic. Dis. 1967;20:637–648
  64. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry. 1998;59(Suppl. 20):22–33
  65. Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Database Syst. Rev. 2004;(2):(CD000967)
  66. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr. Bull. 2003;29:15–31
  67. Tauscher J, Kapur S. Choosing the right dose of antipsychotics in schizophrenia: lessons from neuroimaging studies. CNS Drugs. 2001;15:671–678
  68. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiatry. 1997;154:457–465
  69. van Ameijden EJ, van den Hoek JA, Hartgers C, Coutinho RA. Risk factors for the transition from noninjection to injection drug use and accompanying AIDS risk behavior in a cohort of drug users. Am. J. Epidemiol. 1994;139:1153–1163
  70. van den Hoek JA, van Haastrecht HJ, Coutinho RA. Risk reduction among intravenous drug users in Amsterdam under the influence of AIDS. Am. J. Public Health. 1989;79:1355–1357
  71. van Hoof JJ, Jogems-Kosterman BJ, Sabbe BG, Zitman FG, Hulstijn W. Differentiation of cognitive and motor slowing in the Digit Symbol Test (DST): differences between depression and schizophrenia. J. Psychiatr. Res. 1998;32:99–103
  72. Wechsler D. Manual for the Wechsler Adult Intelligence Scale. New York: Psychological Corporation; 1997;
  73. Wolthaus JE, Dingemans PM, Schene AH, Linszen DH, Knegtering H, Holthausen EA, et al. Component structure of the positive and negative syndrome scale (PANSS) in patients with recent-onset schizophrenia and spectrum disorders. Psychopharmacology (Berl.). 2000;150:399–403
  74. Wudarsky M, Nicolson R, Hamburger SD, Spechler L, Gochman P, Bedwell J, et al. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J. Child Adolesc. Psychopharmacol. 1999;9:239–245

PII: S0920-9964(05)00237-9

doi: 10.1016/j.schres.2005.06.004

Schizophrenia Research
Volume 78, Issue 2 , Pages 147-156 , 15 October 2005

Article Tools